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Abstract
Aims: Averaged measurements, but not the progression based on multiple assessments of carotid intima-media thick-
ness, (cIMT) are predictive of cardiovascular disease (CVD) events in individuals. Whether this is true for conventional
risk factors is unclear.
Methods and results: An individual participant meta-analysis was used to associate the annualised progression of
systolic blood pressure, total cholesterol, low-density lipoprotein cholesterol and high-density lipoprotein cholesterol
with future cardiovascular disease risk in 13 prospective cohort studies of the PROG-IMT collaboration (n¼ 34,072).
Follow-up data included information on a combined cardiovascular disease endpoint of myocardial infarction, stroke, or
vascular death. In secondary analyses, annualised progression was replaced with average. Log hazard ratios per standard
deviation difference were pooled across studies by a random effects meta-analysis. In primary analysis, the annualised
progression of total cholesterol was marginally related to a higher cardiovascular disease risk (hazard ratio (HR) 1.04,
95% confidence interval (CI) 1.00 to 1.07). The annualised progression of systolic blood pressure, low-density lipoprotein
cholesterol and high-density lipoprotein cholesterol was not associated with future cardiovascular disease risk. In sec-
ondary analysis, average systolic blood pressure (HR 1.20 95% CI 1.11 to 1.29) and low-density lipoprotein cholesterol
(HR 1.09, 95% CI 1.02 to 1.16) were related to a greater, while high-density lipoprotein cholesterol (HR 0.92, 95% CI
0.88 to 0.97) was related to a lower risk of future cardiovascular disease events.
Conclusion: Averaged measurements of systolic blood pressure, low-density lipoprotein cholesterol and high-density
lipoprotein cholesterol displayed significant linear relationships with the risk of future cardiovascular disease events.
However, there was no clear association between the annualised progression of these conventional risk factors in
individuals with the risk of future clinical endpoints.
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Risk factors, CVD biomarker, risk factor progression
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Introduction
Cardiovascular disease (CVD) is still the leading cause
of mortality and morbidity in western countries.1, 2
Carotid intima-media thickness (cIMT) is an estab-
lished non-invasive ultrasound biomarker of subclinical
atherosclerosis, and is positively associated with the
risk of future CVD events.3 However, we previously
reported that annualised cIMT progression, assessed
with repeated measurements over a 2–6-year period
for individuals in general population cohort studies
was not associated with future CVD event risk.4 The
explanation for this apparent contradiction is uncer-
tain, but may be related to a low signal-to-noise ratio
and diverse demographics of the patient populations in
PROG-IMT.
Single time point measurements of traditional CVD
risk factors (i.e. systolic blood pressure (SBP), total chol-
esterol (TC), low-density lipoprotein (LDL) cholesterol
and high-density lipoprotein (HDL) cholesterol) show
strong associations with future CVD event risk.5,6
Interestingly, studies prior to the year 2000, which
assessed whether the progression of these traditional
risk markers was associated with the risk of future
CVD events, reported that a decrease in SBP over a
5-year period and increases in TC over a 10-year
period were both related to a higher risk of future
CVD events.7, 8 However, more recent studies reported
no clear consensus on whether the progression of SBP,
TC, LDL-cholesterol and HDL-cholesterol in individ-
uals is associated with future CVD events due to newer
medications and better control of these factors.9, 10
Therefore, we aimed to assess whether the annualised
progression of the above-mentioned traditional risk fac-
tors is associated with future CVD event risk. To draw
parallels to the previous cIMT investigation,4 we used
the same statistical methods and included only PROG-
IMT cohorts with at least two measurements for SBP,
TC, LDL-cholesterol or HDL-cholesterol.
Methods
Study identification and procedures
Inclusion criteria for PROG-IMT have been described
elsewhere.4 A more detailed description can be found in
the Supplementary files (online). Briefly, a comprehen-
sive PubMed search for the following criteria was per-
formed: longitudinal observational studies, sample of or
similar to the general population, well-defined inclusion
criteria and recruitment strategy, at least two visits with
assessment of cIMT, clinical follow-up after the second
visit recording myocardial infarction (MI), stroke, death,
vascular death, or a combination of these. Publications
in all languages published until 10 January 2012 were
included. Furthermore, articles referenced in reviews
on cIMT were manually searched. When a study satis-
fied the inclusion criteria, the study teams were invited to
participate in the project and contribute a predefined
individual participant dataset.11 Initially, 22 population
studies were identified as potential participants.
However, two of these declined participation in the pro-
ject, one did not reply to the invitation, and three
accepted but did not submit their data on time to be
included in the analysis. Of the remaining 16 cohorts,
only 13 were included in the current analysis involving
34,072 individuals (Table 1) as these required at least
two measurements of SBP, TC, LDL-cholesterol or
HDL-cholesterol.12–23 All datasets underwent central
plausibility checks, the variables were harmonised, trans-
formed to SI units, and ordinal variables were recoded
into balanced binary categories.4 The clinical endpoints
(MI, stroke, vascular death and total mortality) were
defined as in the original studies (Supplementary Table
1). Probable or definite MI and any stroke (symptoms
lasting more than 24 hours, including non-traumatic
haemorrhages) were included.
Statistical analysis
We reproduced the analysis used to assess the associ-
ation of annualised cIMT progression and future CVD
event risk.4 All individuals who experienced stroke or
MI prior to the second visit were excluded. Annualised
risk factor progression for each individual was defined
as the difference between visits 2 and 1, divided by the
time separation in years. For each cohort a Cox regres-
sion model for the effect of annualised risk factor pro-
gression on the risk of future CVD events (combined
endpoint of MI, stroke, or vascular death) was calcu-
lated. In studies not reporting vascular death, the com-
bined endpoint MI, stroke, or death from any cause
was used instead.
Three levels of adjustment were used:
Model 1: Age and sex
Model 2: Model 1 plus risk factor average from the
two time points
Model 3: Model 2 plus ethnic origin, socioeconomic
status, and average and progression of other confound-
ing risk factors (SBP (not included for analyses of
SBP), antihypertensive and lipid-lowering medication,
TC (not included for analyses of TC, LDL-cholesterol
and HDL-cholesterol), body mass index, smoking, dia-
betes, creatinine and haemoglobin)
Ethnic origin and socioeconomic status (based on
profession, income or education) were defined differ-
ently in each study. The average and progression of
binary variables were included as four categories: (a)
present at baseline and at follow-up; (b) present at
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baseline but not at follow-up; (c) not present at baseline
but present at follow-up; and (d) not present at either
baseline or follow-up. In the case that a confounding
risk factor was not available at the follow-up visit,
adjustment was made for the baseline confounding
risk factor only; if not available at baseline, no adjust-
ment was made (Supplementary Table 2). We pooled
the log hazard ratio (HR) estimates per standard devi-
ation (SD) increase of the different studies by random
effects meta-analysis24 and displayed them in forest
plots. Heterogeneity was assessed with the I2 statistic.25
Even though outliers were present in some studies, their
frequency was very low that their exclusion did not
change the results.
Secondary and sensitivity analyses
In addition to the models on annualised risk factor
progression, we assessed the association of the average
of the two visits for each risk factor with the risk of
future CVD events (models 2 and 3). As pharmaco-
logical treatment may influence the underlying risk
associations, individuals taking antihypertensive medi-
cation (definition based on each study), statins (or other
lipid-lowering medication) or antidiabetics at either
visit were excluded for a sensitivity analysis.
Individuals without antihypertensives, statins or anti-
diabetics are referred to as ‘individuals without cardio-
vascular medication over time’.
For three studies (ARIC, KIHD, INVADE) risk fac-
tors were available for four visits. We explored a poten-
tial correlation between risk factor progression in
individuals from visits 1 to 2 and from visits 3 to 4.
Inappropriate confounder adjustment
Multivariable regression models which explore the influ-
ence of change (or progression) of a parameter from
baseline to follow-up in observational studies adjusted
for potential confounding factors need to adjust for the
average of that parameter and not the baseline value
alone. Adjusting for baseline alone would be inappropri-
ate because it is artificially correlated with the change
through regression to the mean.26,27 As previous
research has often adjusted for baseline alone, we
aimed to demonstrate how this would affect the results
of our analysis. In particular, we calculated a ‘sensitivity
analysis’ for the relation between the annualised progres-
sion of SBP and future CVD risk by adjusting for base-
line SBP rather than average SBP.
Results
The baseline demographics and CVD events for each
study are shown in Table 1. The average time between
risk factor measurements ranged from 2.2 to 6.6 years.
The means and SDs for the annualised progressions
and for the averages of each risk factor in each study
are shown in Supplementary Table 3.
Association of the annualised progression of SBP, TC,
LDL-cholesterol and HDL-cholesterol with future
CVD event risk
All results discussed in this section relate only to model
3. The results for models 1 and 2 are provided in
Supplementary Figures 1 and 2, respectively. A one
SD larger progression of increase in TC was associated
with a greater risk of the combined endpoint (HR 1.04,
95% confidence interval (CI) 1.00 to 1.07). The annual-
ised progression of SBP, LDL-cholesterol and
HDL-cholesterol was not significantly associated with
the future CVD event risk (Figure 1). There was no
heterogeneity in HRs between studies (Figure 1,
Supplementary Table 4).
Association between average SBP, TC, LDL-choles-
terol and HDL-cholesterol of the two time points with
future CVD event risk
A one SD greater increase in average SBP (HR 1.20,
95% CI 1.11 to 1.29) and average LDL-cholesterol
(HR 1.09, 95% CI 1.02 to 1.16) was associated with a
greater risk of future CVD events. A one SD increase in
average HDL-cholesterol was related to a lower risk
(HR 0.92, 95% CI 0.88 to 0.97; Figure 2). Average
TC was not significantly related to future CVD event
risk. The associations of SBP and TC displayed signifi-
cant heterogeneity between studies, while those for
LDL-cholesterol and HDL-cholesterol did not
(Figure 2, Supplementary Table 5).
Sensitivity analysis
In the analyses of individuals without cardiovascular
medication over time, the sample size was reduced by
about half, which altered the results. In these analyses,
the annualised progression of SBP, TC and LDL-cho-
lesterol was not associated with the risk of future CVD
events. A one SD increase in HDL-cholesterol progres-
sion was related to a lower risk (HR 0.92, 95% CI 0.86
to 0.99) of future CVD events. There was no hetero-
geneity with regard to HRs from the different studies
for all risk factors (Supplementary Table 6).
In subjects without cardiovascular medication over
time, a one SD increase in average SBP (HR 1.28, 95%
CI 1.17 to 1.41) and LDL-cholesterol (HR 1.14, 95%
CI 1.06 to 1.23) was associated with a greater risk of
future CVD events. No significant relationship was
found for average TC. A lower risk was identified for
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each SD increase in average HDL-cholesterol (HR
0.90, 95% CI 0.82 to 0.98; Supplementary Table 7).
In all subjects, using meta-regression across studies,
there was no relationship between the log HRs for pro-
gression and the time interval between measurements
for any of the risk factors.
Consequences of inappropriate confounder
adjustment
The results for this analysis are shown in
Supplementary Figure 3. Adjustment for baseline SBP
rather than average SBP resulted in a significantly posi-
tive association between annualised SBP progression
and the risk of future CVD events (HR 1.08, 95% CI
1.02 to 1.14).
Correlation of risk factor progression
There were no significant correlations of annualised
SBP, TC, LDL-cholesterol and HDL-cholesterol pro-
gression in individuals from visits 1 to 2 with the
progression from visits 3 to 4 (Table 2).
Discussion
We have here found that, similar to cIMT, averaged
measurements of SBP, LDL-cholesterol and
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Figure 1. Hazard ratios (HRs) per one standard deviation (SD) increase in annualised risk factor progression for systolic blood pressure
(SBP) (a), total cholesterol (TC) (b), low-density lipoprotein (LDL) cholesterol (c) and high-density lipoprotein (HDL) cholesterol (d). HRs
are for the risk of the combined endpoint. HRs adjusted for vascular risk factors (model 3, see text). Weights are from random effects
analysis. AIR: Atherosclerosis and Insulin Resistance study; ARIC: Atherosclerosis Risk In Communities Study; CAPS: Carotid
Atherosclerosis Progression Study; CHS: Cardiovascular Health Study; EAS: Edinburgh Artery Study; INVADE: Interventionsprojekt
zerebrovaskula¨re Erkrankungen und Demenz im Landkreis Ebersberg; KIHD: Kuopio Ischaemic Heart Disease Study; PLIC: Progression
of Lesions in the Intima of the Carotid; SHIP: Study of Health in Pomerania; Rotterdam: Rotterdam Study; Tromsø: Tromsø Study.
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HDL-cholesterol displayed significant linear relation-
ships with the risk of future CVD events, while there
was no association between the annualised progression
of these conventional risk factors in individuals with
the risk of future clinical endpoints (i.e. MI, stroke,
vascular death).5, 28, 29 The annualised progression of
TC displayed a marginally significant positive associ-
ation for the combined endpoint.
Our results agree with recent studies that assessed
the progression of these risk factors and future CVD
event risk. In the Whitehall II study, low baseline car-
diovascular health was associated with a higher risk of
future CVD events, while changes in cardiovascular
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Figure 2. Hazard ratios (HRs) per one standard deviation (SD) increase in risk factor average from the two visits for systolic blood
pressure (SBP) (a), total cholesterol (TC) (b), LDL-cholesterol (c) and HDL-cholesterol (d). HRs are for the risk of the combined
endpoint. HRs adjusted for vascular risk factors (model 3, see text). Weights are from random effects analysis. AIR: Atherosclerosis
and Insulin Resistance study; ARIC: Atherosclerosis Risk In Communities Study; CAPS: Carotid Atherosclerosis Progression Study;
CHS: Cardiovascular Health Study; EAS: Edinburgh Artery Study; INVADE: Interventionsprojekt zerebrovaskula¨re Erkrankungen und
Demenz im Landkreis Ebersberg; KIHD: Kuopio Ischaemic Heart Disease Study; PLIC: Progression of Lesions in the Intima of the
Carotid; SHIP: Study of Health in Pomerania; Rotterdam: Rotterdam Study; Tromsø: Tromsø Study.
Table 2. Spearman correlation coefficients for the annualised
progression of SBP, TC, LDL-cholesterol and HDL-cholesterol
from visits 1 to 2 and visits 3 to 4.
Study SBP TC LDL HDL
ARIC –0.06 0.01 0.02 –0.05
KIHD –0.06 0.03 0.08 –0.03
INVADE –0.04 –0.03 –0.02 –0.01
All correlation coefficients are not statistically significant (i.e. P> 0.05).
SBP: systolic blood pressure; TC: total cholesterol; LDL: low-density
lipoprotein; HDL: high-density lipoprotein.
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health were not related.9 In the Framingham Heart
Study cardiovascular health progression over a 6-year
period was not statistically related to coronary artery
calcification progression.30 Interestingly, results from
the Emerging Risk Factors Collaboration demon-
strated that including repeated measurements of risk
factors slightly improved CVD risk prediction
models.10 Future studies need to focus on differentiat-
ing between individual asymptomatic markers of CVD
and CVD mortality and a better understanding of the
effect of these markers in race-ethnic diverse
populations.
In order to improve the understanding of the rela-
tion between SBP progression and the risk of CVD
events, one needs to differentiate between two types
of analyses: studies adjusting for baseline and those
using average SBP as a confounder. For example, a
Japanese study adjusted for baseline and reported
that SBP progression over a 6-year period was asso-
ciated with an increased risk of stroke.31
Furthermore, a large cohort study similarly reported
that progression to hypertension over a 12-year
period was associated with a higher lifetime CVD
risk.32 However, adjustment for baseline values leads
to ‘regression to the mean’ and therefore may not be
appropriate.14,15,33 Regression to the mean becomes
even more important when repeated measurements
are being performed on the same individual.
Adjusting for baseline alone would not be useful
because it is artificially correlated with the change (see
the Supplementary Appendix (online) for further
explanation).26, 27 Without adjustment for baseline,
SBP progression over a 10-year period was not asso-
ciated with increased CVD risk in a French cohort.34
We also report that SBP progression is not related to
future CVD event risk (Figure 1). Hence, the heteroge-
neous findings are most likely due to this incorrect
adjustment for baseline, although there may be other
reasons for the differential findings between the studies.
In fact, if we adjusted for baseline and not average SBP,
our analysis would show a significantly positive rela-
tionship between SBP progression and future CVD
event risk (Supplementary Figure 3).
A large number of studies which investigated
whether TC, LDL-cholesterol and HDL-cholesterol
progression are associated with future CVD event risk
also adjusted for baseline. In particular, Menotti et al.
reported in a meta-analysis that TC progression over 10
years was positively associated with coronary heart dis-
ease.7 However, with adjustment for average TC, no
significant relation between TC progression and CVD
risk was found.35 HDL-cholesterol progression was
associated with potentially protective effects.29, 36 In
particular, when adjusted for baseline, a HDL-choles-
terol decrease over 2.75 years36 and 14 years,29
respectively, was associated with an increased CVD
risk. We found no such association (Figure 1), although
when we only included individuals without cardiovas-
cular medication over time, a similar inverse associ-
ation between annualised HDL-cholesterol
progression and CVD risk was detected. Therefore, in
our opinion, the adjustment for the baseline value of a
risk factor instead of risk factor average induces a bias
in assessing the true associations between the progres-
sion of conventional risk factors and CVD risk.
Our previous investigation showed that cIMT pro-
gression was not related to the risk of future CVD
events. The previous analysis also showed correlation
coefficients near zero for repeated assessments of cIMT
progression. For the current study we also assessed the
correlation for SBP, TC, LDL-cholesterol and HDL-
cholesterol progression from different visits from three
studies. Similar to our cIMT analysis, all correlations
within the same individual were near zero (Table 2).
Hence, one may wonder how two unrelated events
should be able to predict future CVD risk. These find-
ings demonstrate that the signal-to-noise ratio of the
measure of progression is too low to allow for appro-
priate risk prediction.
Statins and other lipid-lowering medication may
impact the results in general population cohorts by
reducing TC and LDL-cholesterol in individuals with
high cardiovascular disease risk and thereby disrupt the
underlying associations. In particular, if at-risk patients
are treated according to guidelines (e.g. receive statins
to lower LDL-cholesterol) but do not reach their target
risk factor value, physicians may escalate treatment and
thereby influence risk factor progression. This may con-
tribute to the non-significant associations of risk factor
progression and future CVD event risk. In addition,
newer and more potent lipid-lowering medications
have recently been prescribed in many countries.
Implications for public health
We demonstrated that cIMT and conventional risk fac-
tors are similar in that accumulated average measure-
ments but not progression based on multiple
measurements in individuals predict future cardiovas-
cular event risk. Our results suggest that measuring risk
factor progression based on two measurements only a
few years apart has a very low signal-to-noise ratio
which does not allow for appropriate individual risk
prediction. This implies that either more measurements
of risk factors, or measurements taken over a longer
time span, are necessary to enable effective individual
risk prediction. Moreover, we have shown that, in an
analysis of risk factor progression, statistical adjust-
ment for the baseline risk factor value alone is mislead-
ing and should be avoided.
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Take-home message
The progression of conventional risk factors has a low
signal-to-noise ratio and is not associated with future
cardiovascular disease risk.
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